PLK1 and survivin in diffuse large B-cell lymphoma.
Schmidt
Mathias
M
Nycomed GmbH, Byk-Gulden-Str. 2, D-78467 Konstanz, Germany. mathias.schmidt@nycomed.com
D018797:Cell Cycle Proteins / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism*; D008869:Microtubule-Associated Proteins / Q000378:metabolism* / Q000502:physiology; D009363:Neoplasm Proteins / Q000378:metabolism* / Q000502:physiology; D011379:Prognosis; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism* / Q000502:physiology; D011518:Proto-Oncogene Proteins / Q000378:metabolism* / Q000502:physiology; D000077022:Survivin; D000097869:Polo-Like Kinase 1
D018797:Cell Cycle Proteins; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D000077022:Survivin; D000097869:Polo-Like Kinase 1; C107489:BIRC5 protein, human